PDF(Pubmed)
Abstract：
UNASSIGNED: A single immune checkpoint inhibitor (ICI) regimen has limited value in treating advanced bile tract cancer (BTC); therefore, ICI combination therapy is often applied. This meta-analysis aimed to evaluate the effectiveness and safety of ICI combination therapy for advanced BTC.
UNASSIGNED: The study protocol was registered on PROSPERO (CRD42023452422). Data on the median progression-free survival (PFS), median overall survival (OS), objective response rate (ORR), disease control rate (DCR), and grade ≥3 adverse events (AEs) reported in relevant studies were pooled and analyzed to determine the efficacy and safety of ICI combination therapy.
UNASSIGNED: In total, 15 studies with 665 patients were included in this meta-analysis. The overall ORR and DCR were 34.6% and 77.6%, respectively. The overall median PFS and OS were 6.06 months [95% confidence interval (CI): 4.91-7.21] and 12.11 months (95% CI: 10.66-13.55), respectively. Patients receiving ICI combination therapy in addition to other therapies had a considerably prolonged median PFS and OS (z=9.69, p<0.001 and z=16.17, p<0.001). Patients treated as first-line treatment had a substantially longer median PFS and OS compared to patients treated as non-first-line treatment (z=11.19, p<0.001 and z=49.17, p<0.001). The overall pooled grade ≥3 AEs rate was 38.2% (95% CI: 0.268-0.497) and was not influenced by whether ICI therapy was combined with other treatments or not or the treatment line.
UNASSIGNED: Advanced BTC patients may benefit from ICI combination treatment without additional AEs. However, concurrent chemotherapy or radiotherapy is still needed to achieve better outcomes.
UNASSIGNED: https://www.crd.york.ac.uk/prospero/, identifier CRD42023452422.
UNASSIGNED: The study protocol was registered on PROSPERO (CRD42023452422). Data on the median progression-free survival (PFS), median overall survival (OS), objective response rate (ORR), disease control rate (DCR), and grade ≥3 adverse events (AEs) reported in relevant studies were pooled and analyzed to determine the efficacy and safety of ICI combination therapy.
UNASSIGNED: In total, 15 studies with 665 patients were included in this meta-analysis. The overall ORR and DCR were 34.6% and 77.6%, respectively. The overall median PFS and OS were 6.06 months [95% confidence interval (CI): 4.91-7.21] and 12.11 months (95% CI: 10.66-13.55), respectively. Patients receiving ICI combination therapy in addition to other therapies had a considerably prolonged median PFS and OS (z=9.69, p<0.001 and z=16.17, p<0.001). Patients treated as first-line treatment had a substantially longer median PFS and OS compared to patients treated as non-first-line treatment (z=11.19, p<0.001 and z=49.17, p<0.001). The overall pooled grade ≥3 AEs rate was 38.2% (95% CI: 0.268-0.497) and was not influenced by whether ICI therapy was combined with other treatments or not or the treatment line.
UNASSIGNED: Advanced BTC patients may benefit from ICI combination treatment without additional AEs. However, concurrent chemotherapy or radiotherapy is still needed to achieve better outcomes.
UNASSIGNED: https://www.crd.york.ac.uk/prospero/, identifier CRD42023452422.
摘要：
■单一免疫检查点抑制剂（ICI）方案在治疗晚期胆管癌（BTC）方面的价值有限；因此，经常应用ICI联合治疗。本荟萃分析旨在评估ICI联合治疗晚期BTC的有效性和安全性。
■研究方案在PROSPERO(CRD42023452422)上注册。有关中位无进展生存期（PFS）的数据，中位总生存期（OS），客观反应率（ORR），疾病控制率（DCR），对相关研究中报告的≥3级不良事件(AE)进行汇总和分析,以确定ICI联合治疗的有效性和安全性.
■总共，该荟萃分析包括15项665名患者的研究。总体ORR和DCR分别为34.6%和77.6%，分别。总体中位PFS和OS分别为6.06个月[95％置信区间（CI）：4.91-7.21]和12.11个月（95％CI：10.66-13.55），分别。除其他治疗外接受ICI联合治疗的患者具有显著延长的中值PFS和OS(z=9.69,p<0.001和z=16.17,p<0.001)。与作为非一线治疗的患者相比,作为一线治疗的患者具有显著更长的中值PFS和OS(z=11.19,p<0.001和z=49.17,p<0.001)。总体合并的≥3级AE率为38.2%(95%CI:0.268-0.497)，不受ICI治疗是否与其他治疗或治疗线联合的影响。
■晚期BTC患者可能会从ICI联合治疗中受益，而不会出现其他不良事件。然而,仍然需要同时进行化疗或放疗才能获得更好的结果.
■https://www.crd.约克。AC.英国/普华永道/，标识符CRD42023452422。
■研究方案在PROSPERO(CRD42023452422)上注册。有关中位无进展生存期（PFS）的数据，中位总生存期（OS），客观反应率（ORR），疾病控制率（DCR），对相关研究中报告的≥3级不良事件(AE)进行汇总和分析,以确定ICI联合治疗的有效性和安全性.
■总共，该荟萃分析包括15项665名患者的研究。总体ORR和DCR分别为34.6%和77.6%，分别。总体中位PFS和OS分别为6.06个月[95％置信区间（CI）：4.91-7.21]和12.11个月（95％CI：10.66-13.55），分别。除其他治疗外接受ICI联合治疗的患者具有显著延长的中值PFS和OS(z=9.69,p<0.001和z=16.17,p<0.001)。与作为非一线治疗的患者相比,作为一线治疗的患者具有显著更长的中值PFS和OS(z=11.19,p<0.001和z=49.17,p<0.001)。总体合并的≥3级AE率为38.2%(95%CI:0.268-0.497)，不受ICI治疗是否与其他治疗或治疗线联合的影响。
■晚期BTC患者可能会从ICI联合治疗中受益，而不会出现其他不良事件。然而,仍然需要同时进行化疗或放疗才能获得更好的结果.
■https://www.crd.约克。AC.英国/普华永道/，标识符CRD42023452422。
